NCT06590051Approved For Marketing不适用
AMG 335 Expanded Access Program for IgG4-Related Disease
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 发起方
- Amgen
研究概览
简要总结
Expanded access requests for AMG 335 may be considered for adult patients with a confirmed diagnosis of IgG4-related disease. To request access, use Responsible Party contact information provided in this record.
研究设计
- 研究类型
- Expanded Access
入排标准
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
No Longer Available
不适用
AMG 714 Expanded Access ProgramCeliac DiseaseNCT03439475Amgen
Available
不适用
AMG 701 Expanded Access ProgramNCT05256446Amgen
Available
不适用
Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CIDPChronic Inflammatory Demyelinating Polyneuropathy (CIDP)NCT04777734argenx
Approved For Marketing
不适用
An Intermediate Size Expanded Access Protocol of AMX0035 for ALSAmyotrophic Lateral SclerosisNCT05286372Amylyx Pharmaceuticals Inc.
Available
不适用
Intermediate-Size Expanded Access Protocol (EAP) for LP352NCT06149663Longboard Pharmaceuticals